ACTC.OB - Sector: Healthcare---Industry: Biotechnology

[tokyopua]

wow, ACTC hammered by a secondary offering apparently, currently down 45%

[setravis]

wow, ACTC hammered by a secondary offering apparently, currently down 45%

Hammered indeed ! 

52wk Range: 0.26 - 2.32
Volume: 21,455,035
Avg Vol (3m): 596,808

Here is the chart.......indicators say drop some more 

[setravis]

Changed Ticker Symbol
'ACTC.OB' is no longer valid. It has changed to ACTC.PK

[setravis]

ACTC.PK - Volume Alert.......
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine.

[setravis]

Press Release Source: Advanced Cell Technology, Inc.


Advanced Cell Provides Corporate Update
Friday January 23, 11:25 am ET 
Company Anticipates Funding to File IND for Retinal Pigment Epithelium (RPE) Cells Program During Summer of 2009


WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC) provided a corporate update today. The Company announced that it has accelerated its efforts to file an IND for its retinal pigment epithelium (RPE) cells program for the treatment of diseases of the eye in light of today's decision by the U.S. Food and Drug Administration to grant clearance for a stem cell company to begin trials for the world's first study of a human embryonic stem cell-based therapy for people. The Company is close to securing the necessary funding which would allow it to make the requisite filings during the summer of this year. An IND filing is required in order to commence clinical trials in humans.


"We believe the recent administration change has increased funding opportunities for technologies such as ours," said William M. Caldwell, CEO and Chairman of ACTC. "Today's decision to allow the world's first study of a human embryonic stem cell-based therapy for people perhaps reflects a new view towards stem cell-based therapies on the part of the FDA and government."

Advanced Cell Technology is currently focused on using its proprietary technologies to generate stable cell lines including retinal pigment epithelium (RPE) cells for the treatment of diseases of the eye, including macular degeneration, which represents a $28 billion dollar market. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 years of age in the United States. AMD is a disorder that affects the macula of the eye that causes decreased visual acuity and possible loss of central vision. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 years of age have the condition.

ACT demonstrated the ability to rescue visual function in rats through implantations of RPE cells derived from human embryonic stem cells. In collaboration with Raymond Lund then at the Moran Eye Institute at the University of Utah and currently working at the Casey Eye Institute at the Oregon Health and Science University, the Company performed RPE transplantation into sub-retinal space of rats that naturally become blind in several weeks due to RPE degeneration and photoreceptor death. In the experiments conducted by the Company, the rats were injected with embryonic stem-RPE cells into the sub-retinal space of the eye at 21 days after their birth — an age at which photoreceptor degeneration has not yet occurred. As control measures, some rats received injections of cell culture medium alone or were not injected at all. Subsequently, tests for visual function were performed at 60 and 90 days after birth — times at which loss of photoreceptor cell has produced characteristic vision deficits. The results represented a major breakthrough. The injected RPE cells grew normally without forming teratomas. Soon, the rats were able to follow lights with their eyes and attained approximately 70% of the spatial acuity of a normal, healthy rat. Necropsy revealed that the eyes had grown layers of the retinal cells. The experiment demonstrated that animals receiving the human embryonic stem cell-derived RPE cells performed significantly better than medium-only treated (50% improvement), or untreated (100% improvement) controls in visual performance. In addition, the human embryonic stem cell-derived RPE cells did not appear to cause any side effects in the animals. The research was published in Cloning and Stem Cells and was also referenced in Scientific American.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.




Contact:
CEOcast, Inc. for Advanced Cell Technology
Daniel Schustack, 212-732-4300

--------------------------------------------------------------------------------
Source: Advanced Cell Technology, Inc.

[setravis]

Nice volume and a nice move been going on.
Soon to have the Golden Cross...

52wk Range: 0.01 - 0.26
Volume: 50,029,944
Avg Vol (3m): 11,840,500


Technicals
Last Price Quote is:
206.29%above 13-day MA
421.59%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $16.36 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/

[setravis]

Long.......Read that GERN and ACTC.PK hold patents for stem cell that may hinder competitors. Also hold GERN long.

52wk Range: 0.01 - 0.29
Volume: 16,315,667
Avg Vol (3m): 13,873,200

Technicals
Last Price Quote is:
41.80%above 13-day MA
172.62%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $24.54 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[la-onda]

in at.13 $

[setravis]

updated chart look...

[setravis]

The upside is blue sky...
For those who bought their risk reward is still out of this world really.
It is that simple.


52wk Range: 0.01 - 0.96
Volume: 16,628,146
Avg Vol (3m): 7,472,000

Technicals
Last Price Quote is:
16.59%above 13-day MA
27.00%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $74.24 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

ACTC news is spreading like wildfire...

http://reason.com/blog/show/133784.html

http://www.kansasliberty.com/liberty-upd...

http://www.transworldnews.com/NewsStory....

http://www.smartbrief.com/news/bio/story...

http://www.telegram.com/article/20090529...

http://slashdot.org/submission/1009533/S...

http://www.sdbj.com/article.asp?aID=9538...

[setravis]

US company finds "safer" way to make stem-like cells
Thu May 28, 2009 5:01pm EDT

*Method could move quickly to human trials, company says
*Bypasses cancer-causing methods to make human stem cells

By Maggie Fox, Health and Science Editor

WASHINGTON, May 28 (Reuters) - U.S. researchers said on Thursday they had come up with the safest way yet to make stem-like cells using a patient's ordinary skin cells, this time by using pure human proteins.

The team at Harvard University and Massachusetts-based Advanced Cell Technology Inc(ACTC.PK) said their technique involves soaking cells in human proteins that turn back the clock biologically, making the cells behave like powerful embryonic stem cells.

Dr. Robert Lanza of Advanced Cell sees almost immediate commercial applications.

"After a few more flight tests -- in order to assure everything is working properly -- it should be ready for commercial use," Lanza said by e-mail.

He said the company would seek Food and Drug Administration permission to test the cells in people by next year -- a process unlikely to be quick, especially with a brand-new technology such as this one.

Stem cells are the body's master cells, giving rise to all the tissues, organs and blood. Embryonic stem cells are considered the most powerful kind, as each one is pluripotent, with the potential to morph into any type of tissue.

Doctors hope to someday use them to transform medicine, for instance, by regenerating the cells destroyed in type 1 diabetes or regrowing eye cells to reverse blindness.

But embryonic cells require the use of an embryo or cloning technology, and several countries, including the United States, limit funding for such experiments.

Several teams of scientists have homed in on four genes that can turn back the clock in ordinary cells, making them look and act like embryonic stem cells. These so-called induced pluripotent stem cells, or iPS cells, could in theory be made using a patient's own skin, allowing grow-your-own transplants with no risk of rejection.

DIFFICULT WORK

Getting these genes into the cells is not easy, however.

The first attempts used retroviruses, which integrate their own genetic material into the cells they infect. Others used loops of genetic material called plasmids or other genetically engineered molecules to reformat the cells.

And another team used the proteins made by the four genes and valproic acid to reprogram cells, but Lanza said these methods all have drawbacks.


His team, working with Kwang-Soo Kim of the Harvard Stem Cell Institute and a team at CHA Stem Cell Institute in South Korea used a peptide, a protein fragment, to drag the human proteins into the cells.

"These have been around for a long time," Lanza said. "The AIDS virus uses the peptide to get into the cells it infects," he said.

Using cells from the foreskins of newborn boys -- a common laboratory technique -- they showed they could transform the cells into iPS cells. They regrew them into a variety of mature new cell types, they reported in the journal Cell Stem Cell.

"This method eliminates the risks associated with genetic and chemical manipulation, and provides for the first time a potentially safe source of iPS cells for translation into the clinic," Lanza said.

"This is the ultimate stem cell solution -- you just add some proteins to a few skin cells and voila! Patient-specific stem cells!"

One question that is not clear is who owns the technology. Lanza said many groups have tried to patent the various steps in the process and it is not yet clear whose patents will prevail.

[setravis]

updated chart look...  

52wk Range: 0.01 - 0.96
Volume: 13,155,559
Avg Vol (3m): 6,100,060

Technicals
Last Price Quote is:
30.91%above 13-day MA
66.72%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $99.23 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

Symmetrical Triangle (Continuation) Pattern
BreakOUT!

The symmetrical triangle, which can also be referred to as a coil, usually forms during a trend as a continuation pattern. The pattern contains at least two lower highs and two higher lows. When these points are connected, the lines converge as they are extended and the symmetrical triangle takes shape. You could also think of it as a contracting wedge, wide at the beginning and narrowing over time.

While there are instances when symmetrical triangles mark important trend reversals, they more often mark a continuation of the current trend. Regardless of the nature of the pattern, continuation or reversal, the direction of the next major move can only be determined after a valid breakout.

Edwards and Magee suggest that roughly 75% of symmetrical triangles are continuation patterns and the rest mark reversals. The reversal patterns can be especially difficult to analyze and often have false breakouts. Even so, we should not anticipate the direction of the breakout, but rather wait for it to happen. Further analysis should be applied to the breakout by looking for gaps, accelerated price movements, and volume for confirmation. Confirmation is especially important for upside breakouts.

Prices sometimes return to the breakout point of apex on a reaction move before resuming in the direction of the breakout. This return can offer a second chance to participate with a better reward to risk ratio. Potential reward price targets found by measurement and parallel trend line extension are only meant to act as rough guidelines. Technical analysis is dynamic and ongoing assessment is required. In the first example above, SUNW may have fulfilled its target (42) in a few months, but the stock gave no sign of slowing down and advanced above 100 in the following months.

[setravis]

I don't know what is going on here....but 

Changed Ticker Symbol
ACTC.PK is no longer valid. It has changed to ACTC.OB   

[setravis]

ACTC Advanced Cell Technology Receives FDA Clearance For the Firs... 


MARLBOROUGH, Mass., Nov 22, 2010 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC) announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

Stargardt's Macular Dystrophy causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium (RPE). . "There is currently no treatment for Stargardt's disease," said Dr. Robert Lanza, ACT's Chief Scientific Officer. "Using stem cells, we can generate a virtually unlimited supply of healthy RPE cells, which are the first cells to die off in SMD and other forms of macular degeneration. We've tested these cells in animal models of eye disease. In rats, we've seen 100% improvement in visual performance over untreated animals without any adverse effects. Our studies showed that the cells were capable of extensive rescue of photoreceptors in animals that otherwise would have gone blind. Near-normal function was also achieved in a mouse model of Stargardt's disease. We hope to see a similar benefit in patients with various forms of macular degeneration."

The Phase I/II trial will be a prospective, open-label study that is designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation to patients with advanced SMD. A total of twelve patients will be enrolled in the study at multiple clinical sites. The sites which are currently under consideration are the Jules Stein Eye Institute at UCLA (headed by Dr. Steven Schwartz); the Casey Eye Institute in Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health Sciences University); the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts (headed by Dr. Shalesh Kaushal, Chair of the Department of Ophthalmology); the UMDNJ -- New Jersey Medical School in Newark, New Jersey (headed by Dr. Marco Zarbin, Chair, Institute of Ophthalmology and Visual Science); additional sites may be considered.

Earlier this year the FDA also granted Orphan Drug designation for the company's RPE cells. As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials such as this one, accelerated FDA approval, and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world's foremost experts in retinal cell physiology and vision restoration, commented, "The study results of ACT's RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."

"Initiating our macular degeneration clinical trial represents a significant milestone in the progress of developing human embryonic stem cell-based therapies aimed at large worldwide markets," said William M. Caldwell IV, ACT's Chairman and CEO. "I think generations will look back at this time as one of the most exciting in the history of medicine. With the initiation of this clinical trial, and that of Geron's earlier this fall, the field of regenerative medicine is poised to take embryonic stem cell therapies from the realm of nebulous potential to that of tangible and real treatments that will make a significant difference in the lives of millions of people worldwide. This is truly a 'game changer' for the medical community."

Among the most common causes of untreatable blindness in the world are degenerative diseases of the retina. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the "dry" form of AMD -- which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.

"These patient numbers are staggering in size," stated Edmund Mickunas, ACT's Vice President of Regulatory, "and when the impact on health and quality-of-life is considered in that context, macular degeneration represents one of the more significant unmet medical needs in our society. With the momentum of this Stargardt's trial, and the unique experience we have gained as one of the few companies in the world having succeeded in taking an hESC program into the clinic, we are preparing to extend our lead with an IND in the use for treating age-related macular degeneration, as well as filing to begin clinical trials in Europe, in the very near future."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com .

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


Investors:
CEOcast, Inc.
Dan Schustack, 212-732-4300
or
Press:
Gotham Communications, LLC
Bill Douglass, 646-450-3615

[setravis]

ACTC - Momentum
http://www.chartmoney.com/stockquotes.php?ticker=actc
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine.